Summary

• Valencia-based iPremom has raised €15 million in seed funding led by Amadeus Capital Partners, with Asabys Partners and APEX Ventures participating.
• Its MaiRa blood test analyses circulating cell-free RNA to estimate pre-eclampsia risk from early pregnancy and is intended to support clinical decisions rather than diagnose the condition.
• Funding will support further clinical validation and commercial rollout, making evidence generation central to the company’s adoption case.

Valencia healthtech company iPremom has raised €15 million to expand clinical validation and commercialise a maternal blood test designed to identify elevated risk of pregnancy complications before conventional symptoms appear.

The seed round was led by Amadeus Capital Partners, with Asabys Partners and APEX Ventures participating. iPremom will use the money to develop and validate its MaiRa platform, which analyses molecular signals in maternal blood and applies predictive software to estimate the risk of complications during pregnancy.

The company’s current MaiRa test focuses on pre-eclampsia, a potentially serious pregnancy complication associated with high blood pressure and organ dysfunction. iPremom says the test can be performed from the ninth week of pregnancy by analysing circulating cell-free RNA in maternal blood, with software producing a risk estimate intended to inform clinical monitoring.

MaiRa is not presented as a diagnostic test. It is designed to help clinicians identify pregnancies that may warrant closer monitoring or preventative intervention, meaning its value depends not only on analytical performance but on whether the additional information changes decisions and outcomes in everyday care.

Prediction has to change clinical care

Pregnancy complications are an attractive target for molecular diagnostics because biological changes can precede symptoms by weeks or months. Detecting those signals earlier creates the possibility of adjusting monitoring, treatment, or preventative care, although an earlier prediction is useful only when its accuracy and clinical consequences are sufficiently well understood.

For pre-eclampsia, timing is particularly important because preventative approaches can depend on identifying elevated risk early in pregnancy. iPremom says MaiRa is intended to support that assessment during the first trimester while complementing existing prenatal testing and medical judgement.

The platform analyses cell-free RNA circulating in maternal blood, including signals associated with the placenta and pregnancy. Unlike genetic tests focused primarily on inherited or chromosomal information, RNA can indicate biological activity, creating an opportunity to identify molecular patterns associated with developing complications.

Translating that science into a dependable clinical product is considerably harder than finding an association in a research dataset. Predictive models need to perform across different populations and healthcare environments, while laboratories require consistent sample collection, processing, quality control, and turnaround times.

Clinicians also need to understand what a given risk score means and what action should follow it. A technically accurate prediction can still produce limited value if the result does not change monitoring or treatment, while a system with poor specificity can generate additional appointments and interventions without improving outcomes.

The financing is therefore tied heavily to validation rather than simple sales expansion. APEX Ventures says the capital will support clinical validation and commercial rollout of MaiRa, giving iPremom resources to generate evidence while developing the operational infrastructure required for broader testing.

Healthtech economics depend on evidence

Diagnostics companies operate differently from conventional software businesses because regulatory clearance or technical performance does not automatically create routine demand. Tests need to fit clinical pathways, persuade clinicians that the information changes care, and often demonstrate to health systems or insurers that the resulting benefit justifies the cost.

A risk test can create expenditure as well as savings if false positives drive extra appointments, scans, or preventative treatment. Conversely, a tool that identifies high risk pregnancies more accurately could direct specialist resources towards patients who need them while avoiding unnecessary intervention elsewhere.

Health-economic evidence consequently becomes part of the commercial proposition rather than an exercise completed after launch. The same applies to integration: clinicians need results at a useful point in the pregnancy, with sufficient clarity to inform decisions and without adding laboratory or administrative steps that overwhelm the value of earlier prediction.

iPremom’s approach sits within a broader move towards blood-based molecular signals that detect disease or risk before overt symptoms appear. Similar methods are being explored in oncology, cardiovascular medicine, transplant monitoring, and prenatal care, supported by cheaper sequencing and more capable computational analysis.

The history of diagnostics, however, includes biomarkers that performed strongly in early datasets before weakening across broader populations. Pregnancy introduces further variation because biological signals change rapidly over gestation, while maternal age, existing conditions, previous pregnancies, treatment, and population characteristics can all influence risk.

iPremom says MaiRa is already available for assessing pre-eclampsia risk, while the newly raised capital will support further validation and commercial expansion. That moves the company towards a harder stage than proving that the underlying molecular signal exists.

Healthcare providers will want to know how performance varies across populations, how the test compares with existing approaches, whether clinicians act on its results consistently, and whether those interventions improve outcomes without creating disproportionate additional care.

The €15 million round therefore places clinical evidence at the centre of the company’s next phase. Molecular data and predictive software may move risk assessment earlier in pregnancy, but wider adoption will depend on proving that earlier information changes care in a way that patients and healthcare systems can rely on.